



Europäisches Patentamt

European Patent Office

Office européen des brevets

Publication number:

**0 197 554
B1**

12

EUROPEAN PATENT SPECIFICATION

45 Date of publication of patent specification: 25.07.90

58 Int. Cl.⁵: **A 61 L 2/16**

21 Application number: **86104849.4**

22 Date of filing: **09.04.86**

64 Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents.

39 Priority: **11.04.85 US 722561**

42 Date of publication of application:
15.10.86 Bulletin 86/42

45 Publication of the grant of the patent:
25.07.90 Bulletin 90/30

64 Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

56 References cited:
**EP-A-0 083 999
EP-A-0 112 563
WO-A-83/04371
US-A-4 305 870
US-A-4 411 795**

78 Proprietor: **Armour Pharmaceutical Company
303 South Broadway
Tarrytown New York 10591 (US)**

72 Inventor: **Chandra, Sudhish
884 South McKinley Avenue
Kankakee Illinois (US)
Inventor: Feldman, Fred
407 Gettysburg
Park Forest Illinois (US)**

74 Representative: **Schmidt-Evers, Jürgen, Dipl.-
Ing. et al
Patentanwälte Dipl.-Ing. H. Mitscherlich Dipl.-
Ing. K. Gunschmann Dipl.-Ing. Dr.rer.nat. W.
Körber Dipl.-Ing. J. Schmidt-Evers Dipl.-Ing. W.
Melzer Steinsdorfstrasse 10
D-8000 München 22 (DE)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.

EP 0 197 554 B1

Description

This invention relates to a method of reducing the pyrogenicity and infectivity of hepatitis B or other viruses in biological and pharmaceutical products. More particularly this invention relates to a method of
 5 inactivating viruses and pyrogens which contaminate biological and pharmaceutical products by adsorbing said products on a solid phase and subjecting them to a treatment with an agent which inactivates viruses and/or pyrogens.

It is well-known that biological and pharmaceutical products may contain transmissible biological contaminants, such as viruses, and especially infectious hepatitis viruses, such as hepatitis virus B, and
 10 non-A, non-B hepatitis viruses. Contamination by viruses may result from both the source material used and from the environment during their production.

Pyrogens are lipopolysaccharides also known as endotoxins, having numerous biologic activities which include the production of fever, activation of clotting mechanisms and induction of shock. Consequently, it is essential that pyrogenic substances be removed from products intended for biological
 15 or pharmaceutical use.

Methods for inactivation or destruction of viruses and/or pyrogens include treatment with heat, acid or alkali, filtration, removal by adsorption with gels, ion-exchange resin and various other such adsorbent material. Most of these methods are burdensome, time consuming, or destructive of the product due to the
 rigorousness of the treatment.

Simple treatment with virus or pyrogen inactivating agents like Triton®, Tween®, beta-propiolactone or hypochlorite may result in inactivation of the viruses and/or pyrogenic materials but is accompanied by partial denaturation of labile proteins. Even if the proteins are not denatured, the quantitative removal of the residual virus inactivating agent or pyrogen inactivating agent may be very difficult and its
 20 contamination makes the biological or pharmaceutical product undesirable.

Illustrative of the use of virus and/or pyrogen inactivating agents is U.S.—A—4,314,957 which discloses the use of amphiphiles to destroy endotoxin and to inactivate hepatitis viruses in plasma derivatives by direct contact of the amphiphiles with the plasma derivatives in solution. After treatment, the plasma proteins are separated from the amphiphiles by precipitation. Such separation may not completely remove the inactivating agents from the precipitated protein and the final product, therefore, may contain
 25 pharmaceutically harmful and/or undesirable inactivating agents.

1. A method to depyrogenate or inactivate viruses in a biological or pharmaceutical product comprising the steps of:

- adsorbing said product onto a solid phase;
- contacting said product adsorbed on said solid phase with a virus inactivating or depyrogenating
 35 agent;
- separating the solid phase from the virus inactivating or depyrogenating agent;
- removing impurities and residual inactivating or depyrogenating agent from the solid phase; and
- recovering the product from the solid phase.

The process of the present invention is applicable to any material in the biomedical field intended to be
 40 used in the human or animal body for biomedical or therapeutic purposes as well as non-therapeutic experimental purposes. Contemplated biomedical products and materials which can be depyrogenated or made free of viruses using the process of the present invention include but are not limited to:

blood fractions such as antihemophilic factor A (AHF, Factor VIII), prothrombin complex (Factors II, VII, IX and X), individual or group of Factor II, Factor VII, Factor IX, Factor X, Protein C, Antithrombin III, C-1
 45 Esterase Inhibitor, Fibronectin, Gamma Globulin, and Albumin derived from human or animal origin; Biological and pharmaceutical products derived from animal origin, e.g. insulin, enzymes, coenzymes, antibodies, and hormones; and biological products derived from human or animal placenta, e.g., blood fractions, and vaccines.

These products and materials are available from various commercial sources or can be produced by
 50 using well-known preparative techniques. For example, blood fractions and blood proteins can be obtained from human blood plasma by fractionation according to known techniques such as, for example, the alcohol fractionation method of Cohn described in U.S. Pat. No. 2,390,074 and the Journal of the American Chemical Society Vol. 68, p. 459 (1946). These methods as well as other techniques are summarized in "The Plasma Proteins", second edition, Volume III, pp. 548—550, Academic Press, New York, N.Y. (1977).

As used herein, the "solid phase" on which said biological or pharmaceutical product is adsorbed is meant to define a substance used as ion exchange, resins used for affinity chromatography, resins with an attached antibody against the particular or related antigen, special membrane media which as an ion
 55 exchanger or are capable of adsorbing particular substances, or glass beads which are treated to produce surfaces that act as an ion exchanger affinity resin. Contemplated solid phase materials include:

60 a, an ion exchanger, e.g., DEAE Sephadex®, QAE Sephadex®, CM-Sephadex®, SP-Sephadex®, DEAE Biogel® A, CM Biogel® A, Biogel® HTP, DEAE Cellulose:

b, resins used for affinity chromatography, such as Sepharose® 2B, Sepharose® 4B, Sepharose® 6B, Sepharose® CL-2B, Sepharose® CL-4B and Biogel® A-15 with an attached ligand consisting of, for example, an inhibitor, enzyme, coenzyme, or hormone. The attached ligand is capable of adsorbing the biological or
 65 pharmaceutical product, for example, heparin attached to a sepharose resin adsorbs Antithrombin III. The

attached ligand may be an antibody to the antigen or related antigen present in the product. An example is antibody to Antihemophilic Factor related antigen attached to a Sepharose resin to adsorb Antihemophilic Factor. The attached ligand may also be a monoclonal or polyclonal antibody to the antigen which might be desired to be isolated as the biological or pharmaceutical product;

c, resins described in b above with an attached antibody (monoclonal or polyclonal) against a particular antigen or an antigen itself;

d, special membrane media which act as an ion exchanger, e.g., Zeta-Prep® cartridge, DEAE, QAE, and SP;

e, controlled-pore glass beads which are treated to produce surfaces that act as an ion exchanger, e.g., DEAE-CPG, CML-CPG; and

f, controlled-pore glass beads attached with biologicals of interest such as inhibitors, enzymes, coenzymes, hormones, antibodies, and antigens.

The virus inactivating and depyrogenating agents used in the present invention are the amphiphiles, organic solvents, hypochlorite or beta propiolactone.

The term amphiphile means a substance containing both hydrophilic water-soluble and hydrophobic water-insoluble groups and which are generally classified as cationic, anionic, ampholytic and non-ionic surface active agents.

Agents of the cationic type include long chain amine condensates with ethylene oxide and quaternary ammonium compounds, for example cetyl trimethyl ammonium bromide and dodecyl dimethyl ammonium bromide. Suitable anionic agents include soaps, salts of aliphatic monoesters of sulphuric acid, for example sodium lauryl sulphate and sodium heptadecyl sulphate, sulphonated aromatic compounds, for example alkyl benzene sulphonic acids and salts thereof such as tridecylbenzene sulphonic acid and the sodium and amino salts of dodecylbenzene sulphonic acid, alkyl naphthalene sulphonates such as sodium butylnaphthalene sulphonate, sulphosuccinates such as sodium dioctyl sulphosuccinate, and N-acyl-N-alkyl fatty acid taurates.

Non-ionic agents include (a) ethoxylated alkylphenols (b) ethoxylated aliphatic alcohols, (c) carboxylic esters and (d) carboxylic amides, as described hereinafter

(a) the ethoxylated alkylphenol non-ionic surface active agents include various polyethylene oxide condensates of alkylphenols, especially the condensation products of mono-alkylphenols or di-alkylphenols wherein the alkyl group contains about 6 to about 12 carbon atoms in either branched chain or particularly straight chain configuration, for example octyl cresol, octyl phenol or nonyl phenol, with ethylene oxide, the said ethylene oxide being present in amounts equal to from about 5 to about 25 moles of ethylene oxide per mole of alkylphenol.

(b) One particular type of ethoxylated aliphatic alcohol non-ionic surface active agents is the condensation products of aliphatic alcohols having from about 8 to 18 carbon atoms in either straight chain or branched chain configuration, for example oleyl or cetyl alcohol, with ethylene oxide, the said ethylene oxide being present in equal amounts of from about 30 to about 60 moles of ethylene oxide per mole of alcohol.

(c) Particular types of carboxylic ester non-ionic surface active agents are firstly the partial, for example mono-esters formed by the reaction of fatty and resin acids, for example of about 8 to about 18 carbon atoms with polyhydric alcohols, for example glycerol, glycols such as mono-, di-, tetra- and hexaethylene glycol, sorbitan, etc; and similar compounds formed by the direct addition of varying molar ratios of ethylene oxide to the hydroxy group of fatty acids.

A second type of carboxylic esters is the condensation products of fatty and resin acid partial, for example mono-esters with ethylene oxide, such as fatty or resin acid esters of polyoxyethylene sorbitan and sorbitol, for example polyoxyethylene sorbitan mono-tall oil esters. These may contain, for example, from about 3 to about 80 oxyethylene units per molecule and fatty or resin acid groups of from about 8 to about 18 carbon atoms. Examples of naturally occurring fatty acid mixtures which may be used are those from coconut oil and tallow whilst examples of single fatty acids are dodecanoic acid and oleic acid.

(d) One particular type of carboxylic amide non-ionic surface active agents is the ammonia, monoethanol and diethanol amides of fatty acids having an acyl chain of from about 8 to about 18 carbon atoms.

The ampholytic agents include dodecyl-alanine, N-dodecylaminoethanesulfonic acid, palmitoyllysocleithin and dodecyl-N-betaine.

Organic solvents which may be used for the process of the present invention include dimethyl ether, diethyl ether, ethyl propyl ether, methyl-butyl ether, methyl isopropyl ether, methyl isobutyl ether, chloroform, methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, n-pentanol and isopentanois.

Referring now specifically to the process steps of the present invention, the product to be treated is first adsorbed onto the solid phase, followed by subjecting the so-adsorbed product to the virus or pyrogen inactivating agent in a liquid or gas phase for sufficient time to complete inactivation and depyrogenation therein. The virus or pyrogen inactivating agent is generally present in amounts of from 0.1% to 50%, preferably from 0.5% to 20%, and most preferably 1% to 10% based on the volume of the product. If the inactivating agent is in the liquid phase, the pH of the solution should be from about 5 to 9 and preferably from about 6 to 8. The time necessary to complete inactivation generally is from 2 minutes to 16 hours, more preferably from 1 to 10 hours. The process of inactivation may be performed at a temperature

EP 0 197 554 B1

ranging from 0°C to 50°C; if the inactivating agents used, are gaseous, the temperature range is generally lower, while liquid phase inactivating agents are employed at or close to room temperature. The inactivating agent in gaseous form can be used as such or as an aerosol spray to treat the solid phase adsorbed product.

5 Preferably, the treatment of the biomedical or pharmaceutical product adsorbed on a solid phase is carried out with the virus or pyrogen inactivating agent, by treating the solid phase adsorbed product with a buffer solution containing an inactivating agent. The treatment is carried out in a column operation or batchwise by immersing or soaking the solid phase in the buffer solution containing the inactivating agent. Suitable buffer solutions include: phosphate, citrate, tris aminomethane, glycine or any other buffering
10 agent which does not adversely interact with the biological or pharmaceutical material being processed.

Upon completing the inactivation step, the inactivating agent is removed by separating the liquid or gas phase from the solid phase. The liquid phase can be separated by the use of a column, by centrifuging or by filtration.

15 Upon completing the separation, the solid phase is washed extensively with a solution of buffer used in the previous step of inactivation, said buffer having an ionic strength of 0.05 M to 2.0 M, and preferably 0.10 M to 0.25 M, and a pH of from about 5 to 9, and preferably from about 6 to 8. The washing is to remove impurities adsorbed on the solid phase and to remove the agent used to depyrogenate or inactivate the virus. This is preferably accomplished in a column or batchwise operation. While a solution of the same buffering agent is preferred to remove impurities and quantitatively remove the inactivating agent, other
20 solutions such as phosphate, citrate, tris, glycine or any buffering agent which does not interact with the biological or pharmaceutical material and has similar ionic strength may also be used.

The pure biological or pharmaceutical product is then eluted from the solid phase with a buffer solution of phosphate, citrate, tris aminomethane, glycine or any other buffering agent which does not adversely interact with the biological or pharmaceutical material being processed and has an ionic strength
25 of 0.15 M to 3.5 M, and preferably from 0.5 M to 2.5 M, and a pH of from about 5 to 9, and preferably from about 6 to 8. Other solutions of sodium chloride, calcium chloride, magnesium chloride, epsilon amino caproic acid, or sodium citrate in a buffer described above may also be used for eluting the pure product.

In order to more fully illustrate the nature of the invention and the manner of practicing the same, the following examples are presented:

TABLE I

	Total CPM	% Of original radioactivity
35 Triton® X-100 containing ³ H Triton X-100 added during 1st wash	167,340,000	100
1st Wash	162,470,000	
2nd Wash	4,350,500	99.93
3rd Wash	507,500	
40 Eluate	11,640	0.0069

Example 1

45 Human plasma fraction, cryopoor plasma, used for Prothrombin Complex isolation, is adsorbed on DEAE-Sephadex®A-50 (Pharmacia). The ion exchanger with Prothrombin Complex proteins adsorbed on it is then treated with Triton X-100 radio labelled with Triton (2% Triton®X-100 containing ³H radio labelled Triton®X-100 which gives a total of 167,340 counts per minute). Triton®X-100 solution is then separated by
50 filtration and the DEAE-Sephadex® is washed three times with a buffer solution (0.01 M sodium citrate, 0.2 M sodium chloride, pH 7.0). During these washings all the Triton X-100 is washed off. Thereafter, Prothrombin Complex is eluted by a buffer of higher ionic strength (0.01 M sodium citrate, 2.0 M sodium chloride, pH 7.0). This eluate is found to be free of Triton® X-100 as shown in Table 1. (As seen in Table I, more than 99.99% of the agent is removed). Thus the agent used to inactivate viruses or pyrogens is
55 quantitatively removed and the final product is free of the agent.

Example 2

60 Plasma fraction used for Prothrombin Complex isolation (plasma from which cryoprecipitate was removed) is spiked with Sindbis or Vesicular Stomatitis virus (VSV). It is then adsorbed on DEAE-Sephadex® and treated with 2% Triton® X-100 solution for 30 minutes to inactivate the virus. The ion exchanger is then separated from Triton X-100 solution by filtration and washed three times with a buffer consisting of 0.01 M sodium citrate and 0.2 M sodium chloride, at pH 7.0, to wash off residual Triton X-100 and impurities bound to DEAE-Sephadex® non-specifically. The Prothrombin Complex is eluted by a buffer of higher ionic strength (2 M sodium chloride, 0.01 M sodium citrate, at pH 7.0), diafiltered, and ultrafiltered
65 to physiological conditions. As control, experiments are repeated after spiking the plasma fractions with

EP 0 197 554 B1

the respective virus. However, treatment of Prothrombin Complex after adsorption on DEAE-Sephadex with 2% Triton X-100 is omitted in the control experiment.

The final Prothrombin Complex, the starting plasma fractions, and intermediate fractions were assayed for virus activity by a method similar to that described by E. R. Pfefferkon and H. S. Hunter (Virology 20, 433—445, 1963), and briefly summarized hereunder.

Chick embryo fibroblasts (CEF) were seeded into 100 mm plastic dishes and allowed to grow to confluence (48 hours). Serial tenfold dilutions of samples were made in minimal essential medium (MEM) containing 10% fetal calf serum and 1.0 ml inoculated onto replicate plates from which culture medium had previously been drained. The plates were incubated for one hour at 37°C in 5% CO₂ after which the inoculum was aspirated and 10 ml per plate of overlay medium added. The overlay medium consisted of MEM with 10% heat inactivated fetal calf serum and 1% agarose. The overlay was allowed to solidify after which cultures were incubated at 37°C in 5% CO₂ for about 24 hours. At this time, cytopathology was evident in positive cultures. A 0.002% solution of neutral red in phosphate buffered saline was then added, and cultures were incubated an additional four hours. After this period, plaques were counted and virus activity was represented in terms of plaque forming units (PFU).

Table II and III show that by treatment with Triton® X-100, using the method described in this invention, virus activities of Sindbis and VSV are reduced 2.07×10^3 and 8.45×10^4 fold respectively as compared to control experiments.

TABLE II
Sindbis inactivation during purification and detergent treatment

	Triton® treatment			Control		
	Vol-ml	Virus amount		Vol-ml	Virus amount	
		PFU/ml	Total PFU		PFU/ml	Total PFU
Starting plasma fraction	10,000	7.76×10^6	7.76×10^{10}	10,000	1.15×10^7	1.15×10^{11}
DEAE-Unadsorbed	10,000	6.10×10^6	6.10×10^{10}	10,000	5.95×10^6	5.95×10^{10}
Wash (Triton®)	500	—	—	—	—	—
Wash—1	3,340	3.90×10^2	1.30×10^6	3,340	5.83×10^5	1.95×10^9
Wash—2	3,340	—	—	3,340	—	—
Wash—3	3,340	—	—	3,340	—	—
Eluate	200	9.83×10^2	1.97×10^5	220	6.83×10^6	1.50×10^9
Prothrombincomplexbulk after UF/DF	152	2.24×10^3	3.40×10^5	201	5.22×10^6	1.04×10^9
Reduction in virus	2.28×10^5 fold			1.10×10^2 fold		
Reduction as compared to control	2.07×10^3 fold					

TABLE III
VSV Inactivation during purification and detergent treatment

	Triton® treatment			Control		
	Vol-ml	Virus amount		Vol-ml	Virus amount	
		PFU/ml	Total PFU		PFU/ml	Total PFU
Starting plasma fraction	10,000	5.0×10^3	5.0×10^7	10,000	4.5×10^3	4.5×10^7
DEAE-Unadsorbed	10,000	1.5×10^3	1.5×10^7	10,000	3.0×10^3	3.0×10^7
Wash (Triton®)	500	—	—	—	—	—
Wash—1	3,340	—	—	3,340	4.0×10^2	1.36×10^6
Wash—2	3,340	—	—	3,340	—	—
Wash—3	3,340	—	—	3,340	—	—
Eluate	300	<0.25	< 7.5×10^1	300	1.93×10^4	5.79×10^6
Prothrombincomplexbulk after UF/DF	216	<0.25	< 5.4×10^1	212	2.91×10^4	6.17×10^6
Reduction in virus	> 9.3×10^5 fold			11 fold		
Reduction as compared to control	> 8.45×10^4 fold					

EP 0 197 554 B1

Example 3

250 ml Cryopoor plasma is spiked with endotoxin to obtain a concentration of 100 ng/ml. The spiked plasma is then stirred with 4 g of preswollen DEAE-Sephadex® to adsorb Prothrombin Complex factors including Factor IX on the resin. The resin is then treated with 2% Triton X-100 solution in 0.01 M sodium citrate, 0.2 M sodium chloride at pH 7.0 to depyrogenate. Thereafter, the resin is washed three times with aliquots of 85 ml solution of 0.01 M sodium citrate, 0.2 M sodium chloride at pH 7.0. Factor IX is then eluted from the resin by a solution of 0.01 M sodium citrate, 2 M sodium chloride at pH 7.0, dialyzed, and ultrafiltered against 0.13 M sodium chloride, 0.01 M sodium citrate at pH 7.0 to a volume of 5 ml. In control experiment treatment of factor IX after adsorption on DEAE-Sephadex with Triton® X-100 is omitted.

The final Prothrombin Complex concentrates thus obtained are assayed for Factor IX potency, clotting factors' activation, and endotoxin. Factor IX is assayed using a slight modification of the one stage method of Barrow and Graham (In Tocantins and Kazel, Blood Coagulation, Hemorrhage and Thrombosis, Grune and Stratton, New York 1964 p. 120), activation measured by the Nonactivated Partial Thromboplastin Time Test (NAPTT) of Kingdon and coworkers (Thromb. Diath. Haemorrh. 33, 617—631, 1975) and endotoxin by a modification of LAL test described by Levin and coworkers (Ann. Intern. Med. 76:1, 1972).

Results presented in Table IV show that treatment with 2% Triton® X-100 using the method of this invention results in practically no impact on Factor IX potency, Prothrombin Complex factors remain in zymogen form (non-activated), and the level of endotoxin is reduced by 70 ng/ml.

TABLE IV

Test	Prothrombin complex concentrate	
	Control	Triton X-100 treated
Factor IX U/ml	23.2	21.6
NAPTT	Negative	Negative
LAL NG/ml	80	10

Examples 1—3 show that by the use of DEAE-Sephadex resin as a solid phase and Triton® X-100 as virus inactivating or depyrogenating agent, proteins of Prothrombin Complex, e.g., Factor IX, are depyrogenated and depleted of virus contamination and the end product results in having no residual amounts of Triton® X-100.

Example 4

Depyrogenation of plasminogen by treatment with Triton® X-100 on lysine-sepharose solid phase

Plasma is spiked with endotoxin at a final concentration of 20 ng/ml, then it is applied on a column consisting of lysine-sepharose resin. Plasminogen is adsorbed to the column. In the column, resin is then treated with 2% Triton® X-100 to depyrogenate it. Residual Triton® is then removed by washing with 0.3 M phosphate buffer at pH 7.3, and plasminogen is eluted by a solution of 0.2 M epsilon amino caproic acid on 0.05 M phosphate buffer at pH 7.3. Finally, the eluate is dialyzed against phosphate buffered saline solution at pH 7.3, and a purified preparation of plasminogen with less than 0.1 ng endotoxin per ml is obtained.

Example 5

Inactivation of vesicular stomatitis virus (a marker) during isolation of antithrombin III by treatment on heparin-sepharose, solid phase

Heparin attached to sepharose is packed in a column. Cryopoor plasma is spiked with VSV to a titer of 5×10^6 total PFU and passed through this column. Antithrombin III is adsorbed on the solid phase, which is then treated with 2% Triton® X-100 in phosphate buffered saline to inactivate the virus. The column is then washed extensively with 0.5 M sodium chloride in phosphate buffer, at pH 7.3, to remove residual Triton® X-100 and the impurities bound nonspecifically to the solid phase. Thereafter, Antithrombin III is eluted by 2 M sodium chloride in phosphate buffer at pH 7.3. The Antithrombin III is then dialyzed against phosphate buffered saline at pH 7.3 to obtain a final purified Antithrombin III preparation in which the virus was reduced to less than 0.25 PFU/ml.

Example 6

Inactivation of viruses at the solid phase consisting of monoclonal antibody against factor VIII:R ligand attached to sepharose during isolation of Factor VIII

Monoclonal antibody against Factor VIII:R Ag is attached to sepharose resin, and packed in a column. A suspension of cryoprecipitate is spiked with VSV, as a controlled experiment, to a concentration of approximately 5×10^7 PFU. It is then passed through the column where Factor VIII molecules (which consist of subunits of Factor VIII:C Antigen and Factor VIII:R Antigen) adsorb through the Factor VIII:R Antigen portion of the molecule. The resin is then treated with 2% Tween® 80 solution in a wash buffer consisting of 100 mM lysine, 20 mM histidine, 0.15 M sodium chloride, at pH 7.0, to inactivate the virus. Residual Tween®

EP 0 197 554 B1

80 solution in a wash buffer consisting of 100 mM lysine, 20 mM histidine, 0.15 M sodium chloride, at pH 7.0, to inactivate the virus. Residual Tween® 80 is removed by an extensive washing of the column using the above wash buffer. The Factor VIII:C portion of the Factor VIII molecule is then desorbed by an elution buffer consisting of 0.25 M calcium chloride in the wash buffer. Once Factor VIII:C antigen is desorbed, remaining Factor VIII:R antigen is also desorbed by 3 M sodium thiocyanate in the above wash buffer. Both Factor VIII:C and Factor VIII:R solutions are separately concentrated and dialyzed against normal physiological saline to obtain Factor VIII:C (clotting) and Factor VIII:R (von Willebrand) preparations practically free of virus, i.e., less than 0.25 PFU/ml.

Example 7

Isolation of protein C free of viruses by treatment with Triton X-100 at a solid phase consisting of pore glass CPG-DEAE

Cryopoor plasma spiked with a marker virus, e.g., VSV to a concentration of 5×10^6 total PFU is passed through a column packed with CPG-DEAE. Protein C is adsorbed on the column which is then treated with 2% Triton® X-100 in the wash buffer, 0.01 M sodium citrate, 0.2 M sodium chloride, at pH 7.0, to inactivate the marker virus. Residual Triton X-100 and other impurities are removed by washing the column extensively with wash buffer. Protein C is then eluted from the column by 0.25 M sodium citrate, 0.55 M sodium chloride at pH 6.0. The eluate is then dialyzed against normal physiological saline solution and a Protein C preparation free of marker virus, VSV, (less than 0.25 PFU/ml) is obtained.

Various modifications will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention; it is intended that all such modifications be included within the scope of the appended claims.

Claims

1. A method to depyrogenate or inactivate viruses in a biological or pharmaceutical product comprising the steps of:

adsorbing said product onto a solid phase;

contacting said product adsorbed on said solid phase with a virus inactivating or depyrogenating agent;

separating the solid phase from the virus inactivating or depyrogenating agent;

removing impurities and residual inactivating or depyrogenating agent from the solid phase; and recovering the product from the solid phase.

2. The method of claim 1 wherein said solid phase is an ion exchanger resin.

3. The method of claim 1 wherein said solid phase is an affinity resin having attached thereto a ligand capable of adsorbing biological or pharmaceutical products.

4. The method of claim 3 wherein said ligand is an inhibitor, enzyme, coenzyme or hormone.

5. The method of claim 4 wherein said ligand is heparin.

6. The method of claim 1 wherein said solid phase is an affinity resin having attached thereto a monoclonal or polyclonal antibody.

7. The method of claim 6 wherein said antibody is antibody to Antihemophilic Factor antigen.

8. The method of claim 1 wherein said solid phase is controlled-pore glass beads or synthetic membrane adapted to produce ion exchange or affinity effect.

9. The method of claim 8 wherein the controlled-pore glass beads or the synthetic membrane are treated with an agent capable of adsorbing biological or pharmaceutical products, said agent is an inhibitor, enzyme, coenzyme, hormone, antibody or antigen.

10. The method of any of claims 1 to 9 wherein the virus inactivating or depyrogenating agent is an amphiphile, organic solvent, hypochlorite, beta propiolactone or mixtures thereof.

11. The method of claim 10 wherein the amphiphile is anionic, cationic, ampholytic or nonionic.

12. The method of claim 10 or 11 wherein said organic solvent is dimethyl ether, diethyl ether, ethyl propyl ether, methyl butyl ether, methyl isopropyl ether, methyl isobutyl ether, chloroform, methanol, ethanol, propanol, butanol, or pentanol.

13. The method of any of claims 1 to 12 wherein the virus inactivating or depyrogenating agent is in a buffer solution having a pH of 5 to 9 and an ionic strength of 0.05 to 2.0 M, the buffer solution containing a buffering agent selected from citrate, phosphate, borate, acetate, bicarbonate, succinate, maleate, phthalate, imidazole, trisamino methane, glycine, lysine, histidine, or mixtures thereof.

14. The method of any of claims 1 to 13 wherein the virus inactivating or depyrogenating agent is in a gaseous or liquid form.

15. The method of any of claims 1 to 14 wherein the separating of the solid phase from the virus inactivating or depyrogenating agent is by filtration, centrifugation or by a column.

16. The method of any of claims 1 to 15 wherein the removing of impurities and residual inactivating or depyrogenating agent is by washing said solid phase with a buffer solution, said buffer solution containing a buffering agent selected from citrate, phosphate, borate, acetate, bicarbonate, succinate, maleate, phthalate, imidazole, trisamino methane, glycine, lysine, or histidine, said buffer solution having a pH of 5 to 9 and an ionic strength of 0.05 to 2.0 M.

17. The method of any of claims 1 to 16 wherein recovering the product from the solid phase is by

EP 0 197 554 B1

elution with a buffer solution or desorbing agent, the buffering solution containing a buffering agent selected from citrate, phosphate borate, acetate, bicarbonate, succinate, maleate, phthalate, imidazole, trisamino methane, glycine, lysine, histidine or mixtures thereof and the desorbing agent is selected from sodium chloride, calcium chloride, magnesium chloride, epsilon amino caproic acid or sodium citrate and mixtures thereof, the buffer solution having a pH of 5 to 9 and an ionic strength of 0.15 to 3.5 M.

18. The method of any of claims 1 to 17 wherein the biological or pharmaceutical product is a plasma protein, an enzyme, coenzyme, hormone, insulin, derived from human or animal placenta or prepared by recombinant DNA or gene splicing technique.

10 Patentansprüche

1. Verfahren zum Depyrogenisieren und Inaktivieren von Viren in einem biologischen oder pharmazeutischen Produkt, bestehend aus den folgenden Schritten:
Adsorbieren des Produkts auf eine feste Phase,
Inberührungbringen des auf der festen Phase adsorbierten Produkts mit einem Viren inaktivierenden oder depyrogenisierenden Mittel,
Abtrennen der festen Phase von dem Viren inaktivierenden oder depyrogenisierenden Mittel,
Entfernen von Verunreinigungen und restlichem inaktivierenden oder depyrogenisierenden Mittel von der festen Phase und
Rückgewinnung des Produkts von der festen Phase.
2. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß die feste Phase aus einem Ionenaustauscher-Harz besteht.
3. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß die feste Phase aus einem Affinitätsharz besteht, an das ein zur Adsorption von biologischen oder pharmazeutischen Produkten befähigter Ligand gebunden ist.
4. Verfahren gemäß Anspruch 3, dadurch gekennzeichnet, daß der Ligand ein Inhibitor, Enzym, Coenzym oder Hormon ist.
5. Verfahren gemäß Anspruch 4, dadurch gekennzeichnet, daß der Ligand Heparin ist.
6. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß die feste Phase aus einem Affinitätsharz besteht, an das ein monoklonaler oder polyklonaler Antikörper gebunden ist.
7. Verfahren gemäß Anspruch 6, dadurch gekennzeichnet, daß der Antikörper ein solcher gegen das Antigen vom antihämophilen Faktor ist.
8. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß die feste Phase porengeregelte Glaskügelchen oder synthetische Membranen sind, die Ionenaustauscher- oder Affinitäts-Wirkungen zu erzeugen vermögen.
9. Verfahren gemäß Anspruch 8, dadurch gekennzeichnet, daß die porengeregelten Glaskügelchen oder synthetischen Membranen mit einem Mittel behandelt worden sind, das biologische oder pharmazeutische Produkte zu adsorbieren vermag, und wobei das Mittel ein Inhibitor, Enzym, Coenzym, Hormon, Antikörper oder Antigen ist.
10. Verfahren gemäß einem jeden der Ansprüche 1 bis 9 dadurch gekennzeichnet, daß das Viren inaktivierende oder depyrogenisierende Mittel aus einer amphiphilen Substanz, einem organischen Lösungsmittel, Hypochlorit β -Propiolacton oder deren Mischungen besteht.
11. Verfahren gemäß Anspruch 10, dadurch gekennzeichnet, daß die amphiphile Substanz anionisch, kationisch, ampholytisch oder nichtionogen ist.
12. Verfahren gemäß Anspruch 10 oder 11, dadurch gekennzeichnet, daß das organische Lösungsmittel Dimethylether, Diethylether, Ethylpropylether, Methylbutylether, Methylisopropylether, Methylisobutylether, Chloroform, Methanol, Ethanol, Propanol, Butanol oder Pentanol ist.
13. Verfahren gemäß einem jeden der Ansprüche 1 bis 12, dadurch gekennzeichnet, daß das Viren inaktivierende oder depyrogenisierende Mittel eine Pufferlösung mit einem pH zwischen 5 und 9 und einer ionischen Stärke von 0,05 bis 2,0 Mol ist und die Pufferlösung ein Puffersalz, ausgewählt aus einem Citrat, Phosphat, Borat, Acetat, Bicarbonat, Succinat, Maleat, Phthalat, Imidazol, Trisaminomethan, Glycin, Lysin, Histidin oder deren Mischungen enthält.
14. Verfahren gemäß einem jeden der Ansprüche 1 bis 13, dadurch gekennzeichnet, daß das Viren inaktivierende oder depyrogenisierende Mittel als Gas oder Flüssigkeit vorliegt.
15. Verfahren gemäß einem jeden der Ansprüche 1 bis 14, dadurch gekennzeichnet, daß die Abtrennung der festen Phase von dem Viren inaktivierenden oder depyrogenisierenden Mittel durch Filtration, Zentrifugation oder in einer Kolonne erfolgt.
16. Verfahren gemäß einem jeden der Ansprüche 1 bis 15, dadurch gekennzeichnet, daß die Entfernung von Verunreinigungen und restlichem inaktivierenden oder depyrogenisierenden Mittel durch Waschen der festen Phase mit einer Pufferlösung erfolgt, die als Puffersalz ein solches ausgewählt aus einem Citrat, Acetat, Bicarbonat, Succinat, Maleat, Phthalat, Imidazol, Trisaminomethan, Glycin, Lysin oder Histidin enthält und einen pH-Wert zwischen 5 und 9 sowie eine ionische Stärke von 0,05 bis 2,0 Mol aufweist.
17. Verfahren gemäß einem jeden der Ansprüche 1 bis 16, dadurch gekennzeichnet, daß die Wiedergewinnung des Produkts von der festen Phase durch Elution mit einer Pufferlösung oder einem

EP 0 197 554 B1

desorbierenden Mittel erfolgt, wobei die einen pH zwischen 5 und 9 und eine ionische Stärke von 0,15 bis 3,5 Mol aufweisende Pufferlösung ein Puffersalz ausgewählt aus einem Citrat, Phosphat, Borat, Acetat, Bicarbonat, Succinat Maleat, Phthalat, Imidazol, Trisaminomethan, Glycin, Lysin, Histidin oder deren Mischungen enthält sowie das desorbierende Mittel ausgewählt ist aus Natriumchlorid, Calciumchlorid, Magnesiumchlorid, ϵ -Aminocapronsäure oder Natriumcitrat und deren Mischungen.

18. Verfahren gemäß einem jeden der Ansprüche 1 bis 17, dadurch gekennzeichnet, daß das biologische oder pharmazeutische Produkt ein Plasmaprotein, Enzym, Coenzym, Hormon, Insulin ist oder von menschlichen oder tierischen Placenten stammt oder durch Rekombination von DNA oder Genspleißung hergestellt ist.

Revendications

1. Procédé de dépyrogénéation ou d'inactivation de virus dans un produit biologique ou pharmaceutique, comprenant les étapes consistant à:

15 faire s'adsorber ledit produit sur une phase solide;

mettre en contact ledit produit adsorbé sur ladite phase solide avec un agent d'inactivation des virus ou de dépyrogénéation;

séparer la phase solide de l'agent d'inactivation des virus ou de dépyrogénéation;

20 éliminer de la phase solide les impuretés et l'agent d'inactivation ou de dépyrogénéation résiduel; et

recupérer le produit à partir de la phase solide.

2. Procédé selon la revendication 1, dans lequel ladite phase solide est une résine échangeuse d'ions.

3. Procédé selon la revendication 1, dans lequel ladite phase solide est une résine d'affinité sur laquelle est fixé un ligand capable d'adsorber les produits biologiques ou pharmaceutiques.

4. Procédé selon la revendication 3, dans lequel ledit ligand est un inhibiteur, une enzyme, une co-

25 enzyme ou une hormone.

5. Procédé selon la revendication 4, dans lequel ledit ligand est l'héparine.

6. Procédé selon la revendication 1, dans lequel ladite phase solide est une résine d'affinité sur laquelle est fixé un anticorps monoclonal ou polyclonal.

7. Procédé selon la revendication 6, dans lequel ledit anticorps est un anticorps dirigé contre l'antigène

30 du Facteur Antihémophilique.

8. Procédé selon la revendication 1, dans lequel ladite phase solide consiste en billes de verre à pores contrôlés ou en une membrane synthétique adaptée pour produire un effet d'échange d'ions ou d'affinité.

9. Procédé selon la revendication 8, dans lequel les billes de verre à pores contrôlés ou la membrane synthétique sont traitées par un agent capable d'adsorber les produits biologiques ou pharmaceutiques, ledit agent étant un inhibiteur, une enzyme, une co-enzyme, une hormone, un anticorps ou un antigène.

10. Procédé selon l'une des revendications 1 à 9, dans lequel l'agent d'inactivation des virus ou de dépyrogénéation est un amphiphile, un solvant organique, l'hypochlorite, la bêta-propiolactone ou leurs

40 ou non-ionique.

11. Procédé selon la revendication 10 ou 11, dans lequel ledit solvant organique est le diméthyl éther, le diéthyl éther, l'éthyl propyl éther, le méthyl butyl éther, le méthyl isopropyl éther, le méthyl isobutyl éther, le chloroforme, le méthanol, l'éthanol, le propanol, le butanol, ou le pentanol.

12. Procédé selon l'une des revendications 1 à 12, dans lequel l'agent d'inactivation des virus ou de dépyrogénéation est dans une solution tampon ayant un pH de 5 à 9, et une force ionique de 0,05 à 2,0 M, la

45 solution tampon contenant un agent tampon choisi parmi citrate, phosphate, borate, acétate, bicarbonate, succinate, maléate, phtalate, imidazole, trisamino méthane, glycine, lysine, histidine, ou leurs mélanges.

13. Procédé selon l'une des revendications 1 à 13, dans lequel l'agent d'inactivation des virus ou de dépyrogénéation se trouve sous une forme gazeuse ou liquide.

14. Procédé selon l'une des revendications 1 à 14, dans lequel la séparation de la phase solide de l'agent d'inactivation des virus ou de dépyrogénéation s'effectue par filtration, centrifugation ou par une

50 colonne.

15. Procédé selon l'une des revendications 1 à 15, dans lequel l'élimination des impuretés et de l'agent d'inactivation ou de dépyrogénéation résiduel s'effectue par lavage de ladite phase solide avec une solution

55 tampon, ladite solution tampon contenant un agent tampon choisi parmi citrate, phosphate, borate, acétate, bicarbonate, succinate, maléate, phtalate, imidazole, trisamino méthane, glycine, lysine, histidine, ou leurs mélanges, et l'agent de désorption est choisi parmi le chlorure de sodium, le chlorure de calcium, le chlorure de

EP 0 197 554 B1

magnésium, l'acide epsilon aminocaproïque ou le citrate de sodium et leurs mélanges, la solution tampon ayant un pH de 5 à 9 et une force ionique de 0,15 à 3,5 M.

18. Procédé selon l'une des revendications 1 à 17, dans lequel le produit biologique ou pharmaceutique est une protéine plasmique, une enzyme, une co-enzyme, une hormone, l'insuline, provenant de placentas humains ou animaux ou préparés par des techniques d'épissage d'ADN recombinant ou de gènes.

10

15

20

25

30

35

40

45

50

55

60

65